iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
- iRhythm’s next-generation Zio® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio® XT device.
- Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service’s superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings.1
- The Zio monitor ECG device has been worn by over 1 million patients since launching in late 2023.2
SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio® monitor, its next-generation Zio® long-term continuous monitoring (LTCM) patch ECG device, presented at the Heart Rhythm Society’s HRX 2024 meeting.
Building on the high performance of its previous generation Zio® XT device, the Zio LTCM monitor was designed to be smaller and lighter,3 with a waterproof housing and a new breathable adhesive. 4,5 For the study, titled “Performance of a Novel Next-Generation Ambulatory ECG Long-Term Patch Monitor: A Multicenter Post-Market Evaluation,” the investigators sought to determine whether these design enhancements translated into improved, post-market real-world device performance compared to its predecessor.
The investigators compared U.S. post-market real-world data of iRhythm’s next-generation Zio monitor to its prior generation Zio XT device. The new Zio monitor demonstrated fewer early wear terminations (i.e., wear time ≤48 hours; 1.1% vs 2.8%, p
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.